Order Article Reprints

Becerra-Tomás N, Ruiz-Canela M, Hernández-Alonso P, Bulló M, Li J, Guasch-Ferré M, Toledo E, Clish CB, Estruch R, Ros E, et al. Glycolysis Metabolites and Risk of Atrial Fibrillation and Heart Failure in the PREDIMED Trial. Metabolites. 2021; 11(5):306. https://doi.org/10.3390/metabo11050306

Becerra-Tomás, Nerea, Miguel Ruiz-Canela, Pablo Hernández-Alonso, Mònica Bulló, Jun Li, Marta Guasch-Ferré, Estefanía Toledo, Clary B. Clish, Ramon Estruch, Emilio Ros, and et al. 2021. "Glycolysis Metabolites and Risk of Atrial Fibrillation and Heart Failure in the PREDIMED Trial" Metabolites 11, no. 5: 306. https://doi.org/10.3390/metabo11050306

Becerra-Tomás, N., Ruiz-Canela, M., Hernández-Alonso, P., Bulló, M., Li, J., Guasch-Ferré, M., Toledo, E., Clish, C. B., Estruch, R., Ros, E., Fitó, M., Lee, C.-H., Pierce, K., Arós, F., Serra-Majem, L., Liang, L., Razquin, C., Gómez-Gracia, E., Martínez-González, M. A., ... Salas-Salvadó, J. (2021). Glycolysis Metabolites and Risk of Atrial Fibrillation and Heart Failure in the PREDIMED Trial. Metabolites, 11(5), 306. https://doi.org/10.3390/metabo11050306